GALLANT 4 Tesaglitazar vs. Glibenclamide

NCT00255541 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

580

Enrollment

INDUSTRY

Sponsor class

Stopped The development program has been terminated

Conditions

Type 2 Diabetes

Interventions

DRUG: Tesaglitazar
DRUG: Glibenclamide

Sponsor

AstraZeneca